静脉到静脉时间对接受阿基仑赛治疗的复发/难治性大B细胞淋巴瘤患者的影响
该系统综述与Meta分析及真实世界分析比较了阿基仑赛、替沙仑赛和利索基仑赛的静脉到静脉时间(V2Vt),并在阿基仑赛治疗患者中评估V2Vt对疗效与安全性的影响。结果显示阿基仑赛中位V2Vt最短(30.6天),V2Vt≥40天与完全缓解率和总生存显著更差相关。
要点
- 阿基仑赛中位V2Vt为30.6天,短于替沙仑赛48.4天和利索基仑赛35.9天。
- 阿基仑赛V2Vt≥40天较<28天完全缓解率更低(OR 0.61),总生存更差(HR 1.33)。
- 阿基仑赛V2Vt≥28至<40天或≥40天较<28天 prolonged thrombocytopenia 发生率更高(OR 1.44或1.95)。
核心结论
- 结果表明V2Vt影响阿基仑赛治疗患者的结局,CD19-CAR治疗更早输注可能有益。
研究设计与样本
- 系统文献综述和Meta分析比较接受阿基仑赛、替沙仑赛或利索基仑赛治疗的复发/难治性大B细胞淋巴瘤患者的V2Vt差异。
- 使用国际血液和骨髓移植研究中心数据的授权后安全性研究,评估阿基仑赛治疗患者中V2Vt(<28天 vs ≥28至<40天 vs ≥40天)对疗效和安全性结局的影响。
主要发现
- 系统文献综述和Meta分析显示,阿基仑赛治疗患者中位V2Vt最短(30.6天),替沙仑赛为48.4天,利索基仑赛为35.9天。
- 阿基仑赛真实世界分析显示,V2Vt≥40天较<28天完全缓解率显著更低(OR 0.61),较≥28至<40天也显著更低(OR 0.66)。
- 阿基仑赛V2Vt≥40天较<28天总生存显著更差(HR 1.33),较≥28至<40天也显著更差(HR 1.36)。
- 阿基仑赛V2Vt≥28至<40天或≥40天较<28天 prolonged thrombocytopenia 发生率更高(OR 1.44或1.95)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T-cell products axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel) are approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Emerging evidence indicates that delayed CAR T-cell infusion, including prolonged time from leukapheresis to infusion, known as vein-to-vein time (V2Vt), may adversely impact clinical outcomes. We conducted a systematic literature review (SLR) and meta-analysis to identify differences in V2Vt in patients with R/R LBCL treated with axi-cel, tisa-cel, or liso-cel. The impact of V2Vt (<28 days vs ≥28 to <40 days vs ≥40 days) on effectiveness and safety outcomes was evaluated in patients treated with axi-cel enrolled in a post-authorization safety study using the Center for International Blood and Marrow Transplant Research data. SLR and meta-analysis showed that patients treated with axi-cel had the shortest median V2Vt (30.6 days) compared with tisa-cel (48.4 days) or liso-cel (35.9 days). Real-world analysis of patients treated with axi-cel demonstrated that V2Vt ≥40 days was associated with significantly lower complete response rate than V2Vt <28 days (odds ratio [OR], 0.61) or ≥28 to <40 days (OR, 0.66) and significantly worse overall survival than V2Vt <28 days (hazard ratio [HR], 1.33) or ≥28 to <40 days (HR, 1.36). Higher prolonged thrombocytopenia rates were observed in patients with axi-cel V2Vt ≥28 to <40 days or ≥40 days compared with <28 days (OR, 1.44 or 1.95, respectively). Together, these results show the impact of V2Vt on patient outcomes with axi-cel therapy and that earlier infusion with CD19-CAR therapies may be beneficial.
引用
- Locke FL, Siddiqi T, Jacobson CA, et al. Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel. Blood Adv. 2025. PMID: 39883946. doi:10.1182/bloodadvances.2024013656
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。